Gynecological Cancer Drugs Market Size and Share, 2023

363
0
SHARE

Portland, OR — 12/22/2017 — Cancer progresses when normal body cells transform into abnormal cells and continue to grow in an uncontrolled manner. It is named after the body part in which it originates; thus, gynecological cancer refers to a group of cancers that affect the reproductive organs of a female, such as a uterus, endometrium, ovary, peritoneum, fallopian tubes, vagina, vulva, cervix, and muscle & tissue supporting the uterus.

The growth of the global gynecological cancer drugs market is driven by factors such as high incidence of gynecological cancers, growth in importance of targeted drug therapies, increase in investment from government, public & private organizations for the development of novel drugs to treat cancer and increase in risk factors that lead to cancer. However, the market growth is hampered by the high cost of drug development and the threat of failure & adverse effects of cancer drug therapy. Conversely, advancement of cancer drug research and advent of personalized medicine approach are expected to provide numerous opportunities for market growth during the forecast period.

Get the sample copy of industry insight: https://www.alliedmarketresearch.com/request-sample/3411

The global gynecological drugs market was valued at $9,269 million in 2016 and is expected to reach $16,107 million by 2023, growing at a CAGR of 8.1% from 2017 to 2023.

The cervical cancer segment is expected to maintain its dominant position during the analysis period, owing to increase in the prevalence of cervical cancer globally.

Targeted therapy segment is expected to grow rapidly, registering a CAGR of 8.9% throughout the forecast period, owing to increased benefits of targeted therapy over chemotherapy.

Enquire before purchase: https://www.alliedmarketresearch.com/purchase-enquiry/3411

Some Key Findings Of Gynecological Cancer Drugs Market:

– The chemotherapy segment accounted for the nearly two-thirds share of the global market in 2016.

– Cervical cancer segment accounted for more than two-fifths share of the market in 2016.

– The ovarian cancer segment is expected to grow at the fastest CAGR of 10.0% from 2016 to 2022.

– Asia-Pacific is expected to be the fastest growing region, registering a CAGR of 9.8% during the forecast period.

Access Full Summary at https://www.alliedmarketresearch.com/gynecological-cancers-drugs-market

Powered by WPeMatico